Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Biogen 2.736, Henry Schein 3.458.
Biogen vs Henry Schein: Revenue Comparison
Biogen (BIIB) and Henry Schein (HSIC) are peers in Healthcare. Biogen reported revenue of $2.7B as of Q2 2026, compared with $3.5B for Henry Schein. Henry Schein leads on revenue.
Biogen's gross margin is 56.9% versus 31.8% for Henry Schein. Biogen's net margin is 3.6% versus 2.7% for Henry Schein.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Biogen, Henry Schein.| Metric | Biogen | Henry Schein |
|---|---|---|
| Market Cap | - | - |
| Revenue | $2.74B | $3.46B |
| Cost of Revenue | $1.18B | $2.36B |
| Gross Profit | $1.56B | $1.10B |
| Operating Income | $318.00M | $200.00M |
| Net Income | $98.00M | $94.00M |
| R&D Expense | $496.00M | $0 |
| Earnings Per Share | $0.66 | $0.82 |
| Gross Margin | 56.9% | 31.8% |
| Operating Margin | 11.6% | 5.8% |
| Net Profit Margin | 3.6% | 2.7% |
| Free Cash Flow | $490.00M | $196.00M |
| Cumulative Free Cash Flow | $47.88B | $9.89B |
| Operating Cash Flow | $449.00M | $242.00M |
| Cash & Equivalents | $1.28B | $157.00M |